Neumora Therapeutics: A Story Of A Class II Biotech [Seeking Alpha]
Neumora Therapeutics, Inc. (NMRA)
Company Research
Source: Seeking Alpha
Play 55min Summary Neumora Therapeutics' lead asset, Navacaprant, shows weak efficacy in phase 2 trial, casting doubt on its success in upcoming phase 3 trials. The company's AI-driven precision medicine claims have not materialized in clinical trial designs, undermining their differentiation strategy. Valuation models suggest Neumora's stock is overvalued, with a fair valuation significantly lower than the current market price. JulPo/E+ via Getty Images Financial markets, or more broadly, entire economies, are well-known to exhibit a certain level of cyclicality. This is largely explained by mainstream economists through concepts like interest rates or credit cycles, which end up affecting spending and can lead to This article was written by AR Capital Menagement Follower s Follow ARCM is an independent research organization finding its roots in european culture, and was founded on April 20th 2022 in Toronto, Canada. Members of the organization hold extensive
Show less
Read more
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NMRA alerts
High impacting Neumora Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NMRA
News
- Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.MarketBeat
- Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Neumora Therapeutics to Participate in Upcoming Conferences in NovemberGlobeNewswire
- Neumora Therapeutics, Inc. (NASDAQ: NMRA) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $15.00 price target on the stock, down previously from $18.00.MarketBeat
NMRA
Earnings
- 11/12/24 - Miss
NMRA
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- NMRA's page on the SEC website